The Translational Breast Cancer Research Consortium was well represented at the 2013 SABCS.  Presentations included:

PIK3CA Mutations and/or Low PTEN Predict Resistance to Combined Anti-HER2 Therapy with Lapatinib and Trastuzumab and without Chemotherapy in TBCRC 006, a Neoadjuvant Trial of HER2-Positive Breast Cancer Patients; Abstract #PD1-2

TBCRC 013 A Prospective Analysis of the Role of Surgery in Stage IV Breast Cancer; Abstract #P2-18-09

Nodal Patterns of Care in Patients with Invasive Breast Cancer Treated with Neoadjuvant Systemic Therapy:  Results of a secondary analysis of TBCRC 017 Abstract #P1-01-04

Significance of circulating tumor cells in metastatic triple negative breast cancer: results of an open label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel with or without the anti-death receptor 5 tigatuzumab (TBCRC 019) Abstract #P1-04-01